The ProShares Pet Care ETF (PAWZ) is a passively managed exchange-traded fund that seeks to track the FactSet Pet Care Index. The underlying index measures the performance of companies positioned to benefit from interest in, or spending on, pet ownership. Under normal circumstances, the fund invests at least 80% of its total assets in index components or instruments with similar economic characteristics.
The portfolio is concentrated, holding roughly 36 securities, and is non-diversified. Its largest positions include online pet retailer Chewy, animal-health leaders Zoetis and IDEXX Laboratories, fresh-pet-food maker Freshpet, and France's Virbac, a veterinary pharmaceutical company. Additional notable names include pet insurer Trupanion, Merck, Oil-Dri, Colgate-Palmolive, and Petco. When screening for comparable holdings, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Sector allocation skews toward healthcare at roughly 44%, reflecting animal-pharmaceutical and diagnostic exposure, with consumer cyclical near 22% and consumer staples around 21%. By geography, the United States accounts for roughly 65% of assets, followed by the United Kingdom, France, Switzerland, and Canada. The fund charges a 0.50% expense ratio and maintains a relatively small asset base in the low tens of millions of dollars.
Pet care has evolved from a discretionary niche into a structurally resilient consumer category. Household pet ownership remains elevated, and spending on veterinary services, premium nutrition, and pet insurance has proven comparatively defensive during periods of economic uncertainty. This backdrop supports the long-term demand drivers behind the fund's animal-health, diagnostics, and specialty-retail holdings.
At the same time, the theme spans several distinct market segments with different dynamics. Animal-health and diagnostics companies, such as Zoetis and IDEXX Laboratories, are influenced by clinic visit volumes, biologic and pharmaceutical demand, and pricing power. Consumer-focused names like Chewy and Freshpet respond to e-commerce adoption, premiumization, and household budget sensitivity. The mixed healthcare and consumer profile means the ETF is exposed to both defensive, recurring-revenue businesses and more cyclical retail spending.
Macroeconomic conditions remain relevant. Inflation trends and interest-rate expectations shape valuation multiples across growth-oriented healthcare and consumer names, while foreign-exchange movements matter given the fund's roughly one-third non-U.S. weighting. Consolidation and innovation in animal health also continue to influence the competitive landscape.
PAWZ has been volatile over the trailing year, trading within a wide range from the high-$40s to the low-$60s. The fund weakened through much of the third quarter, with shares reaching the mid-$46 level in late September and early October, near the bottom of its 52-week range. That decline coincided with pressure on several large healthcare and consumer holdings and reflected broader risk-off conditions in the theme.
The most recent stretch has been markedly different. From the mid-$46 area in early October, the fund staged a sharp recovery into the mid-$55 range by mid-November, a rise of roughly 20% off its lows and a move of nearly 10% over the most recent 30-day window. The rebound was broad-based but concentrated in the portfolio's largest positions, with strength in animal-health and diagnostics names and renewed momentum in pet e-commerce and premium-nutrition holdings contributing most to the recovery. Sizable single-day gains in early November suggest a catalyst-driven, rather than purely gradual, advance. I reviewed the recent patterns using Tickeron’s AI Real Time Patterns to confirm the timing of the move.
Despite the rebound, the fund's relatively thin trading volume and modest asset base can amplify price swings and widen bid-ask spreads, a structural consideration for investors evaluating positioning and execution.
Several structural factors are likely to shape PAWZ through 2026. In animal health, the earnings cycles of Zoetis, IDEXX Laboratories, and Virbac will remain central, with clinic utilization, biologic demand, and product innovation serving as key variables. For the consumer segment, e-commerce share gains at Chewy and Freshpet's capacity expansion and margin trajectory will influence the fund's retail-driven holdings.
The macroeconomic environment also matters. The path of interest rates and inflation will continue to affect valuation multiples for growth-oriented healthcare and consumer names, while foreign-exchange shifts could impact the non-U.S. portion of the portfolio. Household spending resilience will be a swing factor for discretionary pet purchases even as veterinary care retains its defensive characteristics.
Finally, thematic ETF competition and capital flows are worth watching. As a small, non-diversified fund, PAWZ's performance can be influenced by sector rotation into or out of defensive and consumer themes, and by the relative appeal of pet-care exposure versus broader healthcare and consumer strategies. Monitoring holdings-level fundamentals, regulatory developments in veterinary medicine, and institutional positioning will provide the most useful context for assessing the fund's trajectory.
In my own work, Tickeron’s AI Screener has become a practical way to scan for thematic ETFs and compare sector exposures quickly. The platform lets me apply technical indicators, fundamentals, and AI signals to surface patterns across similar holdings without manual effort. I find it especially useful when evaluating smaller funds like PAWZ against broader peers in healthcare and consumer categories.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Stochastic Oscillator for PAWZ moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 65 similar instances where the indicator exited the overbought zone. In 57 of the 65 cases the stock moved lower. This puts the odds of a downward move at 88%.
The 10-day RSI Indicator for PAWZ moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 17 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Moving Average Convergence Divergence Histogram (MACD) for PAWZ turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAWZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
PAWZ broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
PAWZ moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PAWZ crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.
Following a +5.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAWZ advanced for three days, in 227 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 158 of 229 cases where PAWZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows